Clicky

MAGLE CHEMOSWED HOLDING(52X)

Description: Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. The company was founded in 1944 and is based in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.


Keywords: Parkinson's Disease Hypertension Treatment Of Parkinson's Disease Central Nervous System Disorders Benign Prostatic Hyperplasia Uterine Fibroid Treatment Of Central Nervous System Disorders Manufacturing Organization Anticoagulant L Dopa Treatment Of Benign Prostatic Hyperplasia Amantadine Isradipine Liver And Lung Tumors Melperone Hydrochloride Microsphere Technology Pharmaceutical And Medical Device Industry

Home Page: www.maglechemoswed.com

AgneslundsvAegen 27
Malmö, 212 15
Sweden
Phone: 46 7 61 64 33 12


Officers

Name Title
Mr. Hans Henrik Lidgard Founder & Chairman
Mr. Justin Pierce Chief Executive Officer
Ms. Petra Jonsson Sjolin Chief Financial Officer
Mr. Fredrik Andersson Chief Operations Officer
Ms. Megi Medzmariashvili Legal Counsel
Ms. Helena Ossmer Thedius Chief Marketing & Innovation Officer
Mr. Simon Jegou Chief Strategy Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 19.7143
Price-to-Book MRQ: 1.2028
Price-to-Sales TTM: 0.2643
IPO Date:
Fiscal Year End: December
Full Time Employees: 147
Back to stocks